RPTR 147 2
Alternative Names: RPTR-147-2Latest Information Update: 21 Nov 2022
At a glance
- Originator Repertoire Immune Medicines
- Class Antineoplastics; Gene therapies; Immunotherapies; Interleukins; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Interleukin 15 replacements; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Oct 2022 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (Parenteral) due to limited effect
- 24 Oct 2018 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (Parenteral) (NCT03815682)